Efficacy of a Low-Dose Omeprazole-Based Triple-Therapy Regimen for Helicobacter pylori Eradication Independent of Cytochrome P450 Genotype
Authors:
- 1 January 2005
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 25 (5) , 293-305
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pharmacogenomics of proton pump inhibitorsPharmacogenomics, 2004
- Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patientsJournal of Gastroenterology, 2003
- Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazoleClinical Pharmacology & Therapeutics, 2002
- Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus ReportAlimentary Pharmacology & Therapeutics, 2002
- The GU‐MACH study: the effect of 1‐week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcerAlimentary Pharmacology & Therapeutics, 1999
- The DU‐MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapyAlimentary Pharmacology & Therapeutics, 1999
- Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I StudyHelicobacter, 1996
- Medical Treatment of Peptic Ulcer DiseaseJAMA, 1996
- Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of GastroenterologyJAMA, 1996
- Helicobacter pylori in Peptic Ulcer DiseaseJAMA, 1994